[December 15, 2017] |
|
Farydak 2016-2017 U.S Promotional Report - Research and Markets
The "Farydak
2016 U.S Promotional Report" report has been added to Research
and Markets' offering.
The 5 Key Questions Addressed by this Report:
-
How many physicians were reached by Farydak through personal promotion
in 2016 and how does this compare to its peer set in the Multiple
Myeloma markets?
-
What promotional mix was leveraged (e.g., sales rep detailing,
physician education, and paid speaking) and what was the median spend
on each type of activity?
-
How does Novartis's depth of coverage vary within key specialties
(e.g., Hematology/Oncology, Medical Oncology, Internal Medicine, and
Radiation Oncology) and how does this compare to its peers and the
overal set of rep-accessible physicians?
-
How often are physicians receiving paid meals for Farydak throughout
the year (e.g., monthly, quarterly, annually)?
-
Who were the most detailed prescribers and top paid speakers for
Farydak in 2016?
Data Sources and Methodology:
-
We leverage company-reported financial transaction data disclosed
through CMS Open Payments. This data set captures all transfers of
value (e.g., speaking fees, consulting fees, travel, education, and
meals) made on behalf of a drug or device manufacturer to a physician.
Currently, 42 months of longitudinal data is available - covering
payments to more than 900,000 U.S. healthcare professionals.
-
Over 2,500 paid interactions across 1,300 physicians made on behalf of
Farydak were carefully examined to support our analysis. In addition,
interaction data from 7 peer products (e.g. Darzalex, Empliciti,
Kyprolis, Ninlaro, Pomalyst, Revlimid, and Velcade ) was leveraged to
provide benchmarking and market insights.
For more information about this report visit https://www.researchandmarkets.com/research/h4wpkh/farydak_20162017?w=4
View source version on businesswire.com: http://www.businesswire.com/news/home/20171215005474/en/
[ Back To TMCnet.com's Homepage ]
|